Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT04483284
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.

Key Dates

Start date
Jun 24, 2020
Status verified
Jul 2024
Primary completion
Dec 31, 2024
Completion
May 31, 2025

Study Design

Enrollment
28 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TACE combined with Camrelizumab
    Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.

Primary Outcome Measure

Progression Free Survival [ Time Frame: an expected average of 8 months ]

Related Studies